The Claim

Among individuals treated with rosuvastatin, achieving LDL cholesterol levels below 50 mg/dL is associated with a 65% lower incidence of major cardiovascular events compared to those with LDL cholesterol levels of 50 mg/dL or higher.

Source: Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
59score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

People taking rosuvastatin who lower their LDL cholesterol to below 50 mg/dL have a 65% lower rate of heart attacks, strokes, or other major cardiovascular events than those whose LDL cholesterol remains at or above 50 mg/dL.

See the scientific wording

Among individuals treated with rosuvastatin, those who achieve LDL cholesterol levels below 50 mg/dL experience a 65% lower risk of major cardiovascular events compared to those who do not reach this threshold, suggesting a graded relationship between the degree of LDL-C reduction and cardiovascular benefit.

Why this might work

Rosuvastatin blocks cholesterol production in the liver, causing liver cells to pull more bad cholesterol out of the blood. Lower cholesterol in the blood means less buildup in artery walls, which stops plaques from growing and becoming unstable. This prevents plaques from rupturing and triggering blood clots that cause heart attacks and strokes.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

    People taking rosuvastatin who got their bad cholesterol below 50 mg/dL had 65% fewer heart attacks and strokes than those who didn’t reach that level, and the study confirms this exactly—without more side effects.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.